Home » Product News: Growth Direct Systems for Environmental Monitoring and Sterility
Product News: Growth Direct Systems for Environmental Monitoring and Sterility
Bedford, MA – Rapid Micro Biosystems, the provider of rapid, automated, non-destructive detection and enumeration technologies in microbiology, today announced the 2013 availability of the next generation of Growth Direct applications. The tests are specifically designed for environmental monitoring and sterility applications in pharmaceutical quality control laboratories. Representing a quantum leap from the current sterility and environmental monitoring test methods, the applications are based on the detection of natural auto-fluorescence of microorganisms. The Growth Direct System requires no additional reagents to detect growing colonies.
The Growth Direct System for Environmental Monitoring automates the high volume testing typically found in the combination of air, surface and personnel monitoring.
• Two results in one: Positive results in hours, with continued incubation for final results in half the time of the compendial method.
• Large capacity: Designed to handle high numbers of samples per day.
• Added efficiency: Automated reading of all environmental monitoring tests and data transfer to laboratory information systems (LIMS) frees resources for higher value activities.
• Actionable reporting: System alerts users immediately and trending analysis uncovers developing problems.
• Non-destructive: Analysis is non-destructive, allowing for microbial identification.
The Growth Direct System for Sterility revolutionizes pharmaceutical microbial quality control testing while adhering to the stringent regulatory requirements of sterility testing. Features of the system include the following:
• Positive results in hours: Early, real-time detection of microbial contamination, allowing for faster response to contamination events.
• Non-destructive test: Samples with positive results can continue to grow for additional analysis of the micro organism colony.
• Closed-loop sample prep: Aseptic sample preparation and testing of both aerobic and anaerobic microbes.
• 7 days versus 14: The typical sterility test requires 14 days. The Growth Direct™ for Sterility will provide final results in about half the time.
• Quantitative results: An actual colony count (in colony forming units) is provided at the end of the test, with regular count updates throughout the test.
These new applications build on the existing Growth Direct technology currently used in FDA regulated manufacturing facilities. As with the Growth Direc System for Water and Bioburden, sample preparation mimics the existing method including the ability to integrate to a laboratory information management system (LIMS). Once samples are loaded, the system uses the natural auto-fluorescence of the living cells to automatically analyze and enumerate any growing colonies. User configurable software allows for the creation of alerts on out-of-specification samples, with reporting in colony forming units (CFUs.) The test is non-destructive and uses no reagents, ensuring the availability of the sample for identification.
“These new applications for automated, rapid sterility and environmental monitoring testing address critical microbial quality control testing needs in pharmaceutical manufacturing. Businesses will be able to react quickly to contamination events while increasing productivity and standardizing their QC processes,” said Steve Delity, President and CEO of Rapid Micro Biosystems.
The new systems and applications will be available in the first half of 2013.
Rapid Micro Biosystems
Merck Stops Development of Parkinsonís DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesnít work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »